Δημοσίευση

Prevalence and correlates of persistent intracellular HIV transcription in individuals on efavirenz versus atazanavir-based regimens: A prospective cohort study.

ΤίτλοςPrevalence and correlates of persistent intracellular HIV transcription in individuals on efavirenz versus atazanavir-based regimens: A prospective cohort study.
Publication TypeJournal Article
Year of Publication2018
AuthorsPilalas, D., Skoura L., Margariti A., Chatzopoulou F., Chatzidimitriou D., Tsachouridou O., Zebekakis P., Metallidis S., & Papaioannou M.
JournalPLoS One
Volume13
Issue3
Paginatione0194262
Date Published2018
ISSN1932-6203
Λέξεις κλειδιάAdult, Anti-HIV Agents, Atazanavir Sulfate, ATP Binding Cassette Transporter, Sub-Family B, Benzoxazines, CD4 Lymphocyte Count, CD4-Positive T-Lymphocytes, Drug Therapy, Combination, Female, HIV Infections, HIV-1, Humans, Male, Middle Aged, Multidrug Resistance-Associated Proteins, Prospective Studies, Reverse Transcription, RNA, Messenger, RNA, Viral, Viral Load, Virus Latency, Virus Replication
Abstract

OBJECTIVES: Despite successful virological suppression, HIV transcription frequently persists intracellularly. In this study, we hypothesize that HIV persistent transcription(HIVpt) may affect to a different extent patients on stable efavirenz(EFV) versus atazanavir(ATV)-based regimens. The role of the expression of drug efflux transporters in HIVpt was also investigated.METHODS: We prospectively enrolled 51 virologically suppressed patients on first-line treatment for one year with EFV or ATV combined with emtricitabine and tenofovir and followed them up for one year. Simultaneous ultrasensitive subpopulation staining/hybridization in situ(SUSHI) was performed to identify HIVpt in CD4+ T-cells and in the CD4+CD45RO+ T-cell subpopulation. The differential mRNA expression of P-glycoprotein(P-gp/ABCB1) and multidrug resistance-associated protein-1(MRP1/ABCC1) was also evaluated. Univariate logistic regression models were used to evaluate predictors of HIVpt.RESULTS: In the CD4+ T-cell population, HIVpt affected 13/30 of patients on EFV versus 10/21 on ATV. In the CD4+CD45RO+ T-cell population, HIVpt was present in 14/30 of patients on EFV versus 15/21 on ATV. A trend for association was observed between the risk of HIVpt and ATV treatment in the CD4+CD45RO+ T-cell population (OR 2.86, 95% CI 0.87-9.37, p = 0.083). HIVpt status was not associated with loss of virological suppression or CD4 evolution. We found no evidence of differential expression of the drug efflux transporters P-gp and MRP1.CONCLUSIONS: Further study is required to evaluate whether the HIVpt profile in specific cell populations may differ across different antiretroviral regimens and to elucidate the potential clinical impact.

DOI10.1371/journal.pone.0194262
Alternate JournalPLoS ONE
PubMed ID29534103
PubMed Central IDPMC5849343

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.